Drug
Moxifloxacin
Moxifloxacin: highest development phase Post-Market, developed by Bayer, Ferrer, Zai Lab. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bayer, Ferrer, Zai Lab
Trials
| Drug | Phase | Indication |
|---|---|---|
| Moxifloxacin NCT03609099 | Post-Market | Community-acquired Pneumonia |
| AVELOX | Approved | |
| Moxifloxacin NCT05481528 | Phase 1 | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men |
| Moxifloxacin Oral Tablet NCT06462326 | Phase 1 | Healthy Volunteer |
Latest
No recent events.
Follow Moxifloxacin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.